n/a
Article Publish Status: FREE
Abstract Title:

Berberine enhances the sensitivity of radiotherapy in ovarian cancer cell line (SKOV-3).

Abstract Source:

Saudi Pharm J. 2023 Jan ;31(1):110-118. Epub 2022 Nov 15. PMID: 36685297

Abstract Author(s):

Mohammed S Aleissa, Mohammed Al-Zharani, Lina M Alneghery, Abdulmalik M Aleissa

Article Affiliation:

Mohammed S Aleissa

Abstract:

Berberine, a well-known isoquinoline alkaloid derivative, has a varied range of pharmacological effects. Herein, we notice the radio-modulatory outcome of berberine in cultured ovarian cancer (SKOV-3) cells exposed toγ-rays as radiotherapy (RT). Cells pre-treated with berberine were irradiated byγ-irradiation and the liberation of reactive oxygen species (ROS) was analyzed by flow cytometry. Apoptotic cell death along with the DNA damage associated with protein expressions was projected by flow cytometry and confocal microscopy. Experimental findings established that berberine might be a capable radiosensitizer for treating SKOV-3, because of oxidative DNA damage. Moreover, thestudy of the compound, berberine suggests free energy of binding (ΔG) -7.5 kcal/mol with SKOV-3 and -8.8 kcal/mol of PALB/BRCA2, which proves an effective and compact binding of the complex and is safe for future clinical trials. Thus, our approach is probably to widen the field of study of SKOV-3 and PALB/BRCA2 from the inhibition of these targets as a prospective nutraceutical for the anti-cancer theragnostic candidate.

Study Type : In Vitro Study
Additional Links
Pharmacological Actions : Radiosensitizer : CK(291) : AC(233)

Print Options


Key Research Topics

This website is for information purposes only. By providing the information contained herein we are not diagnosing, treating, curing, mitigating, or preventing any type of disease or medical condition. Before beginning any type of natural, integrative or conventional treatment regimen, it is advisable to seek the advice of a licensed healthcare professional.

© Copyright 2008-2024 GreenMedInfo.com, Journal Articles copyright of original owners, MeSH copyright NLM.